NEW YORK (GenomeWeb News) – BG Medicine today priced a public offering of common stock that is anticipated to bring in $8.9 million in net proceeds.

The Waltham, Mass.-based firm plans to offer 6,452,000 shares of its common stock at $1.55 per share. It also has granted the offering's underwriter a 30-day option to purchase up to an additional 967,800 shares to cover any overallotments.

Lazard Capital Markets is the sole book-running manager for the offering.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.